MARKET

FENC

FENC

Fennec Pharmaceuticals Inc
NASDAQ
9.78
+0.18
+1.82%
Opening 13:30 05/19 EDT
OPEN
9.52
PREV CLOSE
9.60
HIGH
10.07
LOW
9.50
VOLUME
107.20K
TURNOVER
--
52 WEEK HIGH
10.27
52 WEEK LOW
5.65
MARKET CAP
339.55M
P/E (TTM)
-34.3344
1D
5D
1M
3M
1Y
5Y
1D
Fennec grants 50,000 stock options to new hires at $9.75 per share
PUBT · 1d ago
FENNEC PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 1d ago
Fennec Pharma publishes corporate presentation on PEDMARK hearing loss prevention in cisplatin patients
PUBT · 1d ago
Weekly Report: what happened at FENC last week (0511-0515)?
Weekly Report · 1d ago
Wedbush Sticks to Their Buy Rating for Fennec Pharmaceuticals (FENC)
TipRanks · 1d ago
Piper Sandler Sticks to Its Buy Rating for Fennec Pharmaceuticals (FENC)
TipRanks · 4d ago
Fennec Pharmaceuticals Earnings Call Signals Robust Growth
TipRanks · 4d ago
Fennec Q1 FY26 swings to profit of $201,000; net sales rise 72.64% to $15.11 million
PUBT · 5d ago
More
About FENC
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

Webull offers Fennec Pharmaceuticals Inc stock information, including NASDAQ: FENC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FENC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FENC stock methods without spending real money on the virtual paper trading platform.